InvestorsHub Logo
Post# of 250791
Next 10
Followers 826
Posts 119084
Boards Moderated 15
Alias Born 09/05/2002

Re: DewDiligence post# 238314

Friday, 07/16/2021 6:42:10 PM

Friday, July 16, 2021 6:42:10 PM

Post# of 250791
FDA approves MRK’s Vaxneuvance—(f/k/a V114)—pneumococcal vaccine_for_adults:

https://www.merck.com/news/merck-announces-u-s-fda-approval-of-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-for-the-prevention-of-invasive-pneumococcal-disease-in-adults-18-years-and-older-caused-by-15-serot/

Vaxneuvance will compete against PFE’s Prevnar-20, which was FDA-approved for adults a few weeks ago (#msg-164292101).

This is a very large market that could play out as “winner takes all.” PFE has an edge, IMO.

Please see #msg-164292101 for background info on these products.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.